FDA Brief

Warning letters Drugs

FDA warning letter to

Westwood Laboratories LLC

High riskIssued Apr 17, 2024Posted May 14, 2024Division of Pharmaceutical Quality Operations IV

FDA warned Westwood Laboratories after an inspection found inadequate investigations, raw material testing, lab controls, and water/cleaning controls for OTC drugs.

What happened

FDA inspected the Azusa, CA drug manufacturing facility from October 30 to November 20, 2023. It found inadequate complaint investigations, no testing of propylene glycol for DEG/EG, uncontrolled HPLC software and unverified rapid microbial methods, and an unqualified water system plus inadequate cleaning of shared equipment. FDA reviewed the company's December 11, 2023 response and found it inadequate.

What FDA found

  1. The company did not thoroughly investigate complaints and batch failures, including an SPF 30 lot that separated and a lot reported as watery thin.

    21 CFR 211.192
  2. The company did not test each incoming component lot for identity and conformity, including propylene glycol for diethylene glycol and ethylene glycol, and did not establish the reliability of supplier certificates of analysis.

    21 CFR 211.84(d)(1) and 211.84(d)(2)
  3. The company did not properly control its HPLC software, with missing employee-specific logins, admin controls, audit trails, and validation documentation.

    21 CFR 211.160(b)
  4. The company used rapid microbial test plates without verifying that the shortened methods could recover organisms or were suitable for its drug products.

    21 CFR 211.160(b)
  5. The company's water system was not adequately qualified, monitored, or maintained, including no testing for objectionable microorganisms and inadequate conductivity testing.

    21 CFR 211.100(a)
  6. The company did not adequately validate cleaning of equipment shared with animal drugs, devices, and cosmetics, including difficult-to-clean surfaces and in-house cleaning agents.

    21 CFR 211.100(a)

What FDA wants

FDA tells the company to correct the violations promptly and respond in writing within 15 working days with corrective action plans and supporting evidence. FDA also requires DEG and EG test results from retained high-risk component lots within 30 calendar days.

Who should pay attention

  • brands that buy OTC drug products manufactured by Westwood Laboratories
  • companies sourcing propylene glycol or other high-risk drug components
  • firms sharing equipment across drugs, animal drugs, devices, or cosmetics

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk